News for Palisade Bio, Inc. (PALI)

Texas-based Sadot Group Inc. (SDOT) is down over 30 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of Alphabet Inc. GOOGL GOOG rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. The comp...

Market Analysis by covering: Euro US Dollar, Intuit Inc, AutoZone Inc, FTSE 350 Mining. Read 's Market Analysis on Investing.com

Palisade Bio, identified by its ticker PALI, has announced the addition of Emil Chuang to its Board of Directors. Chuang brings nearly 25 years of experience in

Palisade Bio (PALI) appoints Dr. Emil Chuang to its Board of Directors. Dr. Chuang brings nearly 25 years of pharmaceutical and clinical experience, wit

Palisade Bio (PALI) has released encouraging topline results from its Phase 1 trials of PALI-2108, an innovative treatment targeting fibrostenotic Crohn's disea

Palatin Technologies, symbolized as (PALI), has joined forces with Kingswood Capital Partners and Ladenburg Thalmann as the principal book-running managers. Thi

On May 13, 2025, Brookline Capital analyst Kumaraguru Raja reiterated a "Buy" rating for Palisade Bio (PALI). The analyst has maintained the price target at USD

Palisade Bio (PALI) presents positive preclinical data for PALI-2108 at Digestive Disease Week 2025. PALI-2108 shows dose-dependent improvement in colit

**media[611637]**

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, f

Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and t

**media[566623]**

Massachusetts-based iRobot Corporation (IRBT) is down over 35 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

**media[564380]**

Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment

**media[556934]**

**media[544696]**